SCIESCOPUSQ1
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
SAGE PUBLICATIONS INC, United Kingdom
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM is an academic journal published by SAGE PUBLICATIONS INC (United Kingdom). Identifiers: ISSN 1470-3203, eISSN 1752-8976. Indexed in SCIE, SCOPUS. Metrics: JIF 4.1, CiteScore 5.3, SJR 0.750, SNIP 0.82. Subject areas: PERIPHERAL VASCULAR DISEASE, PERIPHERAL VASCULAR DISEASES.
AI JOURNAL FINDER
Is your manuscript a fit for this journal?
Enter your title and abstract to compare with AI Journal Finder’s recommendations.
CiteScore
5.30
Scopus citation metric
SJR
0.750
SCImago rank
SNIP
0.82
Source normalized impact
Percentage rank
-
JIF percentile rank
Journal profile
- ISSN
- 1470-3203
- eISSN
- 1752-8976
- Abbreviation
- J RENIN-ANGIO-ALDO S
- Publisher
- SAGE PUBLICATIONS INC
- Country
- United Kingdom
Web of Science categories
SCIEPERIPHERAL VASCULAR DISEASES
Scopus ASJC categories
1310 Endocrinology2724 Internal Medicine
Keywords
Peripheral Vascular Diseases
Papers in this journal
Recent papers
- Integrating exercise, music, and dance therapies in education to modulate the renin-angiotensin system: Implications for childhood depression
2026 · 1 citations
- Prediction of renal function improvement after percutaneous nephrolithotomy in patients with chronic kidney disease
2026
- GATM-ALDH2-Mediated mitophagy orchestrates macrophage polarization and efferocytosis to suppress AKI-to-CKD progression
2026
- The role of oxidative stress in the pathophysiology of diabetic cardiomyopathy: Crosstalk of inflammatory pathways
2026
- Interactions between AT1, AT2 and B2 receptors in the response to Ang II in the aorta of SHR rats
2026
Most cited papers
- Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension
2007 · 237 citations
- Role of Angiotensin II in Cardiovascular Disease — Therapeutic Implications of More Than a Century of Research
2006 · 236 citations
- The HOPE Study (Heart Outcomes Prevention Evaluation)
2000 · 156 citations
- The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)
2000 · 146 citations
- The renin-angiotensin system meets the hallmarks of cancer
2015 · 143 citations